]>
IRCT20180122038471N1 IRCT 2018-02-08 Urology Research Centre, Guilan University of Medical Sciences The effect of pentoxifylline 400 mg on anemia control and decreasing the dose of erythropoietin Evaluation of the effect of pentoxifylline 400 mg on anemia control and decreasing the dose of erythropoietin in chronic hemodialysis patients 2018-01-05 anticipated 16 Complete https://irct.ir/trial/29135 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the random block method. 3 Anemia. Intervention 1: Intervention group: 400 mg pentoxifylline pill, made in Iran, once daily for 12 weeks, with an appropriate dosage of intravenous erythropoietin for each patient diagnosed by physician. Intervention 2: Control group: Routine care and no additional intervention with an appropriate dosage of intravenous erythropoietin for each patient diagnosed by physician. No - There is not a plan to make this available Justification or reason for not sharing IPD is All patient information is confidential and their publication is not ethically correct. Information will only be published in the form of report or/and scientific paper.
public Samira Rahimi
Razi Hospital, Sardar Jangal Street
Rasht Iran (Islamic Republic of) 41448-95655 +98 13 3352 5259 urc1384@yahoo.com Rasht University of Medical Sciences scientific Pegah Aghajanzadeh
Razi Hospital, Sardar Jangal Street
Rasht Iran (Islamic Republic of) 41448-95655 +98 13 3352 5259 drpegah_a@yahoo.com Rasht University of Medical Sciences Iran (Islamic Republic of) GFR less than 15 Have been under hemodialysis for at least 3 months Performing regular hemodialysis 3 times a week Having an iron saturation of more than 30% and ferritin more than 500 Dialysis adequacy criteria: Kt/V greater than 1/2 Have an arteriovenous fistula or a pacifier for hemodialysis Hemoglobin less than 11 in at least 2 consecutive tests within a month no limit no limit Both History of bleeding in a recent month History of infection leading to hospitalization in a recent month Use of theophylline and androgens Intolerance to drug use in oral form Patient dissatisfaction The patient has undergone blood transfusion or B12 administration for any reason during the last 3 months. The presence of any underlying illness that justifies anemia, including thyroid and parathyroid dysfunction, hemoglobinopathy and malnutrition, and ... Hemorrhagic retinopathy The presence of coronary artery disease in the last 3 months D46.4 Refractory anemia, unspecified Treatment - Drugs Treatment - Other Intervention group: 400 mg pentoxifylline pill, made in Iran, once daily for 12 weeks, with an appropriate dosage of intravenous erythropoietin for each patient diagnosed by physician Control group: Routine care and no additional intervention with an appropriate dosage of intravenous erythropoietin for each patient diagnosed by physician Hemoglobin level. Timepoint: At the beginning of the study (before the intervention) and 4, 8 and 12 weeks after the intervention. Method of measurement: Blood test. Urology Research Centre, Guilan University of Medical Sciences Approved 2017-12-30 Ethics committee of Guilan University of Medical Sciences Opposite the 17th Shahrivar Hospital, Ciadati Ave, Namjoo St. Rasht Guilan Iran (Islamic Republic of)